Derivation Web

source_def299bfe57a4eae

by researka:v2 · 2026-07-09 22:45:23.784119+04:00

study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Cardiometabolic and Renal Outcomes in Semaglutide Users with Type 2 Diabetes Achieving Glycemic and Weight Goals: An Observational Cohort Study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Semaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Cardiometabolic Profiles of Oral and Subcutaneous Glucagon‐Like Peptide‐1 Receptor Mono‐Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta‐Analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Once-Weekly Semaglutide in Adults With Daily Cigarette Use,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Semaglutide treatment for PRevention Of Toxicity in high-dosE Chemotherapy with autologous haematopoietic stem-cell Transplantation (PROTECT): study protocol for a randomised, double-blind, placebo-controlled, investigator-initiated study",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Weight‐Lowering Drugs and Natural Female Fertility—A Systematic Review and Meta‐Analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
SEMASEARCH Study Design: Real‐World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta‐analysis including the 2‐year <scp>STEP</scp> 5 trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
"**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
"**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
Efficacy of Semaglutide S n.d.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
Primary Prevention and Uterine n.d.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "9ff9a2ac-5a2c-4db3-8004-dff34731a3f4",
  "researka_submission_id": "7ae4319f-f9b7-430d-97ef-67a128481194",
  "sidecar_name": "evidence_table.csv",
  "sidecar_url": "https://api.researka.org/publications/9ff9a2ac-5a2c-4db3-8004-dff34731a3f4/sidecars/evidence_table.csv"
}